



PC10303AJTJ

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Elizabeth King, et al.

Examiner: J. Spear  
Group Art Unit: 1615

APPLICATION NO.: 09/425,622

FILING DATE: October 22, 1999

TITLE: Controlled-Release Pharmaceutical Formulations

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

hereby certify that this correspondence  
being deposited with the United States  
Postal Service as First Class Mail in an  
envelope addressed to: Assistant Commissioner  
for Patents, Washington, D.C. 20231 on

this 18th day of July 20 01

By [Signature]

Response Under Rule 111

This in response to the Office Action dated January 18, 2001 in the above-identified application, the term for response having been extended three (3) months by enclosing the appropriate fee and petition herewith.

In response to the Office Action, please make the following changes to the application.

In the claims:

Please amend the claims as follows:

B1  
24. (Amended) A method of treating sexual dysfunction, which comprises administering a controlled-release formulation, as defined in claim 1, but without proviso, to a mammal in need of such treatment.

B2  
30. (Amended) Products containing a controlled-release formulation as defined in claim 1, but without proviso, and a cGMP PDE-5 inhibitor in immediate release form, as a combined preparation for simultaneous, separate or sequential use in the treatment of sexual dysfunction.

REMARKS

The above amendments have been made to improve form, in response to the Office Action.

Applicants have amended claims 24 and 30 by deleting the wording which

RECEIVED  
AUG 01 2001  
TECH CENTER 1600/2900

# 7/B  
HKO  
89-01

B